Unpacking Q1 Earnings BioMarin Pharmaceutical In The Context Of Other Therapeutics Stocks
| RYBOX Fund | USD 56.56 0.45 0.79% |
Slightly above 62% of Biotechnology Fund's investor base is looking to short. The analysis of overall sentiment of trading Biotechnology Fund Class mutual fund suggests that many investors are alarmed at this time. Biotechnology Fund's investing sentiment can be driven by a variety of factors including economic data, Biotechnology Fund's earnings reports, geopolitical events, and overall market trends.
Biotechnology |
As the Q1 earnings season wraps, lets dig into this quarters best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical and its peers.
Read at finance.yahoo.com
 |
Biotechnology Fund Fundamental Analysis
We analyze Biotechnology Fund's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Fund using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Fund based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Biotechnology Fund is currently under evaluation in price to sales among similar funds. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Biotechnology Fund Class Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biotechnology Fund mutual fund to make a market-neutral strategy. Peer analysis of Biotechnology Fund could also be used in its relative valuation, which is a method of valuing Biotechnology Fund by comparing valuation metrics with similar companies.
Peers
Biotechnology Fund Related Equities
| GABTX | Gamco Global | 1.13 | ||||
| CFNLX | National Tax | 0.16 | ||||
| LOISX | Lord Abbett | 0.1 | ||||
| SMAAX | Aig Government | 0.1 | ||||
| AUNTX | Ab Municipal | 0.09 | ||||
| AUNCX | Ab Municipal | 0.09 |
Other Information on Investing in Biotechnology Mutual Fund
Biotechnology Fund financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Fund security.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |